What is the Difference Between Prevnar 13 and PPSV23?

Prevnar 13 (PCV13) and Pneumovax 23 (PPSV23) are both pneumococcal vaccines used to prevent pneumococcal disease, including pneumonia, meningitis, and bacteremia. However, there are differences between the two vaccines:

1. Protection: PCV13 protects against 13 types of pneumococcal bacteria, while PPSV23 protects against 23 types of pneumococcal bacteria.
2. Administration: PCV13 is injected into the muscle (IM), while Pneumovax 23 can be given either in the muscle (IM) or under the skin (subcutaneously).
3. Recommended Intervals: The Advisory Committee on Immunization Practices (ACIP) recommends that PCV13 be given first, followed by PPSV23 6-12 months later.
4. Effectiveness: Studies on PCV13 in adults show it to be 75% effective in preventing invasive disease (like bloodstream infections and meningitis) and 45% effective at preventing non-invasive pneumonia caused by the 13 strains it covers. PPSV23 helps prevent invasive infections like meningitis and bacteremia but offers low levels of protection against pneumonia.

Both vaccines are safe and effective in preventing pneumococcal infection. Most adults over 65 need one dose of each vaccine, given one year apart. The ACIP recommends PCV13 for all adults 65 years or older and adults 19 years or older with certain medical conditions or taking medications that lower the body's resistance to infection. PPSV23 is recommended for all adults 65 years or older and adults 19 years or older with certain medical conditions.

Comparative Table: Prevnar 13 vs PPSV23

Prevnar 13® (PCV13) and Pneumovax 23® (PPSV23) are two pneumococcal vaccines used to protect against different serotypes of Streptococcus pneumoniae. Here is a table comparing the differences between the two vaccines:

Both vaccines aim to induce immunity against Streptococcus pneumoniae, causing pneumonia and other infections. However, they have different compositions and elicit different types of immune responses. The 1-year interval is recommended for sequential use of PCV13 and PPSV23 for immunocompetent adults aged ≥65.